IL6 and systemic sclerosis: As elevated interleukin-6 (IL-6) in SSc-patients has been associated with higher incidence of progressive pulmonary decline, tocilizumab (TCZ) was recently introduced as a therapeutic strategy within the faSScinate study [16, 17].